Zim Laboratories Limited

Registered office: Sadoday Gyan, (Ground floor). Opp. NADT, Nelson Square, Nagpur-440013. Maharashtra, India CIN: U99999MH1984PLC032172, Website: www.zimlab.in

Special Purpose Interim Standalone Financial Results for the Quarter ended 31 December 2016

		Quarter ended 31-12-2016
	Income	Rs. lacs
1.		
	Revenue from operations (gross)	5,686.75
	Less: Excise duty	118.04
	Revenue from operations (net) Other income	5,568.71
		121.31
	Total revenue	5,690.02
II.	Expenses	
	Cost of materials consumed	2,524.97
	Purchase of stock in trade	
	Changes in inventories of finished goods and work-in-progress	311.94
	Employee benefits expense	40.65
	Finance costs	881.60
		342.13
	Depreciation and amortisation expense	227.20
	Other expenses	1,234.05
	Total expenses	5,562.54
III.	Profit / (loss) before tax	127.48
IV.	Tax (expense)/Credit	•)
	Current Tax - Minimum Alternate Tax payable	(26.25)
	Less: Taxes pertaining to Previous years	53.58
	Less: Minimum alternative tax credit entitlement	15.06
	Net Current Tax (Expense)/Credit	42.39
	Deferred Tax (Expense)/Income	42.39
	Total tax (expense)/Credit (net)	42.39
٧.	Net Profit/(Loss) for the period	169.87
VI.	Paid-up equity share capital of Rs.10 each	802.91
VII.	Earnings per share (nominal value of share Rs. 10) (not annualised)	
	Basic (In Rs.)	2.12
	Diluted (In Rs.)	2.09

NOTES:

- This result is prepared in connection with the direct listing of the Company to be filed with the BSE Limited (BSE) or may be shared with and relied on as necessary by the Merchant Bankers duly appointed in this regard or any other regulatory authority in connection with
- 2. The Company has received notice from BSE Limited (BSE) whereby the Company has been provided with an option to either complete the procedures for direct listing of its equity shares on nationwide stock exchange or provide exit to public shareholders by acquiring their equity shares at rates determined by independent valuer. Pursuant to receipt of such notice, the Company has initiated the procedures for direct listing of its equity shares on BSE.
- Basis of Accounting: For the purpose referred in note 1 above, the above financial results have been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standards specified under Companies (Accounting Standard) Amendment Rules 2016, which is in line with the accounting policies adopted in preparation of financial statements at the year end. Further, the above financial results has been prepared with the purpose of summarizing performance of the Company for the three months period from 1 October 2016 to 31 December 2016. Accordingly, comparable figures for any of the previous periods have not been considered in above statement.
- The above results were approved by the Board of Directors of the Company at their meetings held on 21.09.2017.
- 5. The operations of the Company represent a single primary business segment relating to pharmaceuticals.

For and on behalf of the board of directors of Zim Laboratories Limited

Anwar S. Daud

Managing Director

Zulfiquar M. Kamal

Director & CFO

Place: Nagpur Date: 21.09.2017